DMD Fast Forward. Published on January 28, 2008 as doi:10.1124/dmd.107.019570

DMD 19570

METABOLITE GENERATION VIA MICROBIAL BIOTRANSFORMATIONS WITH ACTINOMYCETES: RAPID SCREENING FOR ACTIVE STRAINS AND BIOSYNTHESIS OF IMPORTANT HUMAN METABOLITES OF TWO DEVELOPMENT STAGE COMPOUNDS, BMS-587101 AND DASATINIB[§]

WENYING LI, JONATHAN L JOSEPHS, GARY L SKILES[1] AND W GRIFFITH HUMPHREYS

Department of Biotransformation, Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543

Running title: Metabolite synthesis via microbial biotransformation

Address correspondence to:

Dr. Wenying Li

Bristol Myers Squibb Co.

Department of Biotransformation

Route 206 & Province Line Road

Princeton, NJ 08543

Phone: 609-252-5792

Email: Wenying.Li@BMS.com

[2]Abbreviations used: BMS, Bristol Myers Squibb Co.; P450, cytochrome P450; HPLC, high performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; MS, mass spectrometry; NMR, nuclear magnetic resonance ; RLM, rat liver microsomes ; HLM, human liver microsomes.

# of text pages: 38

# of tables: 4

# of figures: 7

# of references: 35

# of word in abstract: 199

# of words in introduction: 524

# of words in discussion: 1647

ABSTRACT

The enzymes present in many microbial strains are capable of carrying out a variety of biotransformations when presented with drug-like molecules. Although the enzymes responsible for the biotransformations are not well characterized, microbial strains can often be found that produce metabolites identical to those found in mammalian systems. However, traditional screening for microbial strains that produce metabolites of interest is done with many labor intensive steps that include multiple shake flasks and many manual manipulations which hinder the application of these techniques in drug metabolite preparation. A 24-well microtiter plate screening system was developed for rapid screening of actinomycetes strains for their ability to selectively produce metabolites of interest. The utility of this system was first demonstrated with the well-characterized cytochrome P450 substrate diclofenac. Subsequently the use of this system allowed the rapid identification of several actinomycetes strains that were capable of converting two drug candidates under development, BMS-587101 and dasatinib (SPRYCEL®, BMS-345825), to mammalian metabolites of interest. Milligram quantities of the metabolites were then prepared by scaling-up the microbial biotransformation reactions. These quantities were sufficient for initial characterization, such as testing for pharmacological activity and use as analytical standards, prior to the availability of authentic chemically synthesized compounds.

INTRODUCTION

An integral part of the drug discovery and development process involves characterization of the metabolites of a drug candidate. The major purposes of these characterizations are to: 1) help ensure that human metabolites are adequately tested in toxicology species, 2) determine if any of the pharmacological activity of the drug is due to active metabolites, and 3) aid in the determination of the mechanism of metabolic clearance of the parent drug (Baillie, 2002; US FDA, 2005). Standard testing paradigms for ensuring the safety of drug metabolites have been recently proposed and aspects of these proposals were recently reviewed (US FDA, 2005; Guengerich, 2006; Davis-Bruno, 2006; Humphreys, 2006; Smith, 2006). Considerable effort is often required to prepare sufficient quantities of key mammalian metabolites of drug candidates for biological activity evaluation or for use as analytical standards. Metabolite biosynthesis methods using mammalian systems (microsomes, S9, hepatocytes, in vivo, etc.) are useful for generating limited quantities of metabolites for structure elucidation by LC/MS/MS and NMR analysis. Chemical synthesis is the preferred method for larger scale metabolite preparation, but it is often a resource-intensive exercise and certain metabolites present particularly difficult synthetic challenges. In many cases, neither mammalian biosynthesis nor chemical synthesis is particularly effective for making quantities of metabolite useful for initial characterizations (typical early characterization studies require 1-50 mg). Larger quantities can be prepared by chemical synthesis, however, it is often not an efficient use of resources to embark on a multi-step synthesis before gathering any information about the metabolite of interest.

The concept of microbial models of mammalian metabolism has been well established (Smith, 1974). Work in this area has been reviewed (Abourashed, 1999; Azerad, 1999) and there have been an increasing number of reports describing the use of microbial systems to mimic or predict mammalian metabolite formation, and to prepare larger quantities of mammalian metabolites (Moody, 1999 and 2002; Zhang, 2006; Zmijewski, 2006; Xie, 2005). The traditional microbial screening methods utilizing shake flasks are labor intensive, which has likely limited the widespread use of microbial biotransformation in drug metabolism studies. Found mainly in soil, actinomycetes are Gram-positive mycelia bacteria known to produce a diversity of natural products and perform a wide variety of metabolic conversions on molecules with a range of physico-chemical properties. These metabolic conversions include oxidative biotransformations that are similar to those catalyzed by mammalian P450 enzymes. There are more than one hundred known genera of actinomycetes, including streptomyces, actinoplanes, and nocardia. Actinomycetes culturing conditions are amenable to a well-plate format fermentation which makes them attractive bioreactors for metabolite biosynthesis.

A preliminary study examining the ability of a variety of actinomycetes strains to metabolize marketed drugs and produce their respective mammalian metabolites has been previously reported (Li, 2005). In this manuscript, the application of an actinomycetes screening system that led to the rapid synthesis of three mammalian oxidative metabolites of drugs under development, BMS-587101 (Figure 1) and dasatinib (SPRYCEL®, BMS-345825, Figure 2), is described. The three metabolites, M6 (a dehydrogenated metabolite of BMS-587101), M20 and M24 (hydroxylated metabolites of dasatinib; Cui, 2007), were

the major circulating human metabolites that were difficult to synthesize chemically, which made them ideal candidates for microbial biosynthesis.

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

MATERIAL AND METHODS

Materials. BMS-587101 (5-[(5S,9R)-9- (4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid) and dasatinib (*N*-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide) were synthesized at BMS. All other organic solvents and the reagents were of HPLC or reagent grade. Diclofenac (HCl salt), 4'-hydroxydiclofenac, pig liver esterase and catalase were obtained from Sigma Co. (St. Louis, MO). Rat liver microsomes were obtained from Xenotech LLC (Lenexa, KS). The microbial strains were acquired from American Type Culture Collection (with ATCC numbers) or from BMS in-house collections (with SC numbers).

Fermentation. Malt extract medium used in the fermentation was prepared as follows: 20 g dextrose (EM Science, Gibbstown, NJ), 10 g malt extract (Difco, Detroit, MI), 10 g yeast extract (Difco, Detroit, MI) and 1g peptone (Difco, Detroit, MI) were dissolved in one liter deionized water. The pH of the solution was adjusted to approximately 7 with 1N NaOH or 1N HCl. The solution was dispended into containers and autoclaved at 121^{o}C for 30 min. Fermentation was performed at 28°C on a New Brunswick Scientific Innova 4500 environmental rotary shaker (New Brunswick, NJ) with a throw of 2 inches. Shaking speed was 250 to 275 rpm for microtiter plates and 200 to 250 rpm for Erlenmeyer flasks.

NMR analysis: NMR analyses of BMS-587101 metabolites were preformed in methanol- d_4 at 25 °C on a Bruker DRX 500 MHz spectrometer equipped with a 5 mm

TXI cryo probe (Bruker BioSpin Corporation, Billerica, MA), operated at 500.13 MHz for proton and 125.76 MHz for carbon, respectively. NMR analyses of dasatinib metabolites were preformed in DMSO-d_6 at 30 °C on a Bruker Avance 600 MHz NMR spectrometer equipped with a 5 mm TCI cryo probe and a Bruker Avance 700 MHz NMR spectrometer equipped with a 5 mm cryo triple resonance probe.

The proton and carbon chemical assignments were based on 1D and 2D NMR, including ^{1}H-^{1}H-gCOSY (gradient-selected correlation spectroscopy), ^{1}H-^{13}C-HSQC (heteronuclear single-quantum coherence), ^{1}H-^{13}C-HMBC (heteronuclear multiple bond correlation) and ^{1}H-^{15}N-HMBC. ^{13}C chemical shift data were deduced from ^{1}H-^{13}C-HMBC and ^{1}H-^{13}C-HSQC spectra. ^{15}N chemical shift data were deduced from ^{1}H-^{15}N-HMBC spectra. The proton and carbon chemical shifts were referenced to solvents, methanol-d_4 (proton, δ3.30 ppm; ^{13}C, δ49.0 ppm) and DMSO-d_6 (proton, δ2.50 ppm; ^{13}C, δ39.5 ppm). The nitrogen chemical shifts were referenced to $^{15}NH_4{}^{15}NO_3$ at δ20.7 and δ376.3 ppm respectively. The patterns of peaks were reported as singlet (s), doublet (d), triplet (t) or broad (b).

MS analysis: Accurate mass analysis was performed on a Finnigan MAT 900 high-resolution mass spectrometer (ThermoFinnigan, San Jose, CA). LC/MS analysis was performed with a Finnigan LCQ or LTQ ion trap mass spectrometer.

Microbial screening plate. Twenty actinomycetes strains were used (Table 1). A frozen vial (approximately 2 ml) of each selected strain was used to inoculate a 500 ml flask

containing 100 ml of malt extract medium. The culture was incubated for three days at 28°C on a rotary shaker operating at 250 rpm. The resulting culture (0.1 ml) was transferred into a well of a Uniplate (24 well, 10 ml, irradiated, Whatman, Clifton, NJ). Multiple copies of the screening plates, containing one well each of the 20 selected actinomycetes strains, were made and stored at -78 ˚C.

Screening of microbial strains for formation of diclofenac metabolites. One frozen screening plate was thawed at room temperature and 1 ml of malt extract medium was added to each well. The plate was incubated for two days at 28^{o}C on a rotary shaker operating at 275 rpm. Diclofenac (10 µl of 25 mM solution in 1:1 v/v methanol/water) was added to each well and then the plate was incubated with shaking for an additional 24 hours at 28°C. One ml of methanol was added to each well, the plate was shaken at room temperature for 1 hour and centrifuged at 3000 rpm for 15 min. The supernatant (10 µl) was analyzed by HPLC/MS on an Agilent 1100 series HPLC system (binary pump, autosampler, and a Photodiode Array UV detector; Agilent Technologies, Wilmington, DE), which was coupled to a Thermo Finnigan LTQ ion trap mass spectrometer. Samples were injected onto a YMC ProC18 column (2.0 x 50 mm, S5, Waters Corporation, Milford, MA) and separated at a flow rate of 0.2 ml/min using mobile phases consisting of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The solvent gradient was as follows: 20% B for 2 min, 20% to 90% B in 20 min. The elution was monitored with UV detection at 295 nm. Metabolites of diclofenac were detected based on their MS and product ion spectra obtained by positive ion electrospray

with data dependent MS/MS. The identity of 4'-hydroxy-diclofenac (Stierlin, 1979) was confirmed by comparison with an authentic standard.

Biosynthesis of BMS-587101 M6 metabolite with rat liver microsomes. The incubation contained 100 mM potassium phosphate buffer (pH 7.5), 360 μM BMS-587101, 1.2 mg/ml catalase, 2 mg/ml rat liver microsomal protein and 2 mM NADPH in a total volume of 50 ml. The reaction mixture was extracted twice with ethyl acetate (70 ml each time). The ethyl acetate extracts were combined and solvent was removed with a rotary evaporator. The residue was dissolved in 0.6 ml methanol and subjected to semi-preparative HPLC separation with a YMC ODS AQ 20x150 mm, S5 column (Waters Corporation, Milford, MA). The mobile phases were 1 mM HCl in water (A) and acetonitrile (B). The gradient used was: 20% B for 5 min, 20% to 50% B in 2 min, 50% to 75% B in 36 min. The flow rate was 10 ml/min with UV detection at 230 nm. Under these conditions M6 eluted at approximately 31 min. Fractions containing M6 were pooled and lyophilized. Approximately 20 μg of M6 ((S)-5-((9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-8-en-7-yl)methyl)thiophene-3-carboxylic acid) was obtained as an HCl salt.

Characterization:

LC/MS: -ESI $[M-H]^-$: *m/z* 551; MS2: *m/z* 551→ *m/z* 507.

1H NMR (500 MHz, CD_3OD): δ ppm 2.81 (s, 3H), 3.76 (d, *J* = 12.4 Hz, 1H), 3.81 (d, *J* = 12.4 Hz, 1H), 4.53 (d, *J* = 15.4 Hz, 1H), 4.68 (d, *J* = 15.4 Hz, 1H), 7.17 (d, *J* = 8.8 Hz, 2H), 7.45 (s, 1H), 7.50 (t, *J* = 1.8 Hz, 1H), 7.53 (d, *J* = 1.8 Hz, 2H), 7.55 (d, *J* = 8.6 Hz, 2H), 7.62 (s, 1H), 8.13 (s, 1H).

Screening of microbial strains for formation of BMS-587101 metabolite M6. One frozen screening plate was thawed at room temperature and 1 ml of malt extract medium was added to each well. The plate was incubated for two days at 28^{o}C on a rotary shaker operating at 250 rpm. BMS-587101 (10 µl of 18 mM solution in DMSO) was added to each well and then the plate was incubated with shaking for an additional 18 hours at 28°C. One ml of methyl-t-butyl ether (MTBE) was added to each well, the plate was shaken at room temperature for 30 min and centrifuged at 3000 rpm for 15 min, and then the supernatant from each well was transferred to an HPLC vial and solvent was removed under a stream of nitrogen gas. The residue in the vial was then dissolved in ethanol (200 µl) and analyzed by HPLC. HPLC analyses were performed on an Agilent 1100 series HPLC system. Samples were injected onto a YMC ODS AQ column (4.6 x150 mm, S3, Waters Corporation, Milford, MA) and separated in 15 min at a flow rate of 1 ml/min using mobile phases consisting of 1 mM HCl in water (solvent A) and acetonitrile (solvent B). The solvent gradient was as follows: 30% B for 2 min, 30% to 55% B in 1 min, 55% to 80% B in 8 min, 80% to 90% B in 1 min, 90% for 2 min, 90% to 30 % B in 1 min. The elution was monitored with UV detection at 240 nm.

Preparation of BMS-587101 metabolite M6 by microbial biotransformation. From the frozen stock culture of *Actinomycetes sp.* SC 15850, 2 ml was used to inoculate 100 ml of malt extract medium. The culture was incubated for 3 days at 28^{o}C on a rotary shaker operated at 250 rpm. Two ml of this culture was used to inoculate each of two 500-ml flasks containing 100 ml of malt extract medium. The flasks were incubated at

28°C on a rotary shaker operated at 250 rpm for 24 hours. Ten milligrams of BMS-587101 in 1 ml DMSO was added to each flask and the culture was returned to the shaker and incubated for an additional 12 hours at 28°C and 220 rpm. At the end of the incubation, cultures from the two flasks were pooled and extracted with 100 ml MTBE. The MTBE extract was completely evaporated with a rotary evaporator. The residue was dissolved in 0.6 ml of methanol and subjected to semi-prep HPLC separation with a YMC ODS AQ 20x150 mm, S5 column. The mobile phases were 1 mM HCl in water (A) and acetonitrile (B). The gradient used was: 20% B for 5 min; 20% to 45% B in 15 min; 45% B for 30 min; 45 % to 53% B in 20 min; 53 % B in 20 min. The flow rate was 10 ml/min with UV detection at 230 nm. The fractions containing M6 and an amide derivative of M6 eluted at 76 and 56 min, respectively. The pure M6 and M6-amide fractions were pooled accordingly and lyophilized. M6 (HCl salt, 2.5 mg) (HRMS (ESI) calculated for $C_{26}H_{18}Cl_2N_4O_4S$ $[M-H]^-$: 551.0348; found: 551.0354. LC/MS/MS and proton NMR data were consistent with M6 isolated from the RLM incubation) and M6 amide (HCl salt, 3.5 mg) (HRMS (ESI) calculated for $C_{26}H_{19}Cl_2N_5O_3S$ $[M+H]^+$: 552.0664; found: 552.0659) were obtained as white solids.

Preparation of BMS-587101 metabolite M6 via hydrolysis of the amide. A 500-ml flask containing sodium phosphate buffer (0.1 M, pH 8.0), pig liver esterase (176 U), methanol (2 ml) and amide of M6 (HCl salt, 27 mg) was incubated for 4 days at 37^{o}C on a rotary shaker operating at 180 rpm. At the end of the incubation, the reaction mixture was extracted with MTBE (400 ml). The MTBE was removed from the extract with a rotary evaporator. The residue was dissolved in 1 ml of methanol and subjected to semi-prep HPLC separation with the following conditions: column, YMC ODS AQ 20x150

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

mm, S5; mobile phases, 1 mM HCl in water (A) / acetonitrile (B). The gradient used was: 20% B for 5 min; 20% to 45% B in 5 min; 45% B for 80 min with a flow rate of 10 ml/min and UV detection at 230 nm. The fractions containing pure M6 were pooled and lyophilized. M6 (HCl salt, 9.1 mg) (HRMS (ESI) calculated for $C_{26}H_{18}Cl_2N_4O_4S$ $[M-H]^-$: 551.0348; found: 551.0356. LC/MS/MS and NMR (proton, ^{1}H-^{1}H-gCOSY ,^{1}H-^{13}C-HSQC,^{1}H-^{13}C-HMBC) data were consistent with M6 isolated from the RLM incubation) was obtained as a white solid.

Screening of microbial strains for formation of dasatinib metabolites M20 and M24. One frozen screening plate was thawed at room temperature and then 1 ml of malt extract medium was added to each well. The plate was incubated for two days at 28^{o}C on a rotary shaker operated at 275 rpm. Dasatinib (2 µl of a 100 mM solution in DMSO) was added to each well and the plate was incubated for an additional 23 hours at 28°C on a rotary shaker operating at 275 rpm. One ml of methanol was added to each well and then the plate was incubated at 28^{o}C at 150 rpm for 10 min and centrifuged at 3000 rpm for 15 min. The supernatant was analyzed by HPLC/MS. HPLC/MS analysis was performed on an Agilent 1100 series HPLC system, which was coupled to a Thermo Finnigan LTQ ion trap mass spectrometer. Samples were injected onto a Phenomenex Synergy Polar-RP 2.0x150 mm (Phenomenex, Torrance, CA) and separated in 28 min at a flow rate of 0.2 ml/min using mobile phases consisting of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The solvent gradient was as follows: 20% B for 1 min, 20% to 22.1% B in 5 min, 22.1% to 90% B in 1 min, 90% B for 2 min, 90% to

20% B in 1 min, 20% B for 3 min. The elution was monitored with UV detection at 320 nm and MS detection (dasatinib HPLC method 1).

An HPLC/UV method was used to separate M20 and M24 with a YMC ODS AQ column (4.6x150 mm, S3) using mobile phases consisting of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) at a flow rate of 1 ml/min. The solvent gradient was as follows: 20% B for 1 min, 20% to 25% B in 13 min, 28% to 80% B in 1 min, 80% B for 3 min, 80% to 20% B in 12 min, 20% B for 3 min. The elution was monitored with UV detection at 320 nm and MS detection (dasatinib HPLC method 2).

Preparation of dasatinib metabolite M20 by microbial biotransformation. From the frozen stock culture of *Streptomyces sp*. strain SC15761, 2 ml was used to inoculate a 500 ml flask containing 100 ml of the malt extract medium. The flask was incubated for three days at 28°C on a rotary shaker operated at 250 rpm. One ml of the resulting culture was added to each of eleven 500 ml flasks containing 100 ml of the malt extract broth. The cultures were incubated at 28°C and 250 rpm for 47 hours. Dasatinib solution in DMSO (200 µl of a 48.9 mg/ml solution) was then added to each of the eleven flasks. The flasks were returned to the shaker and incubated for an additional 27 hours at 28°C and 250 rpm. The reaction cultures were pooled and extracted twice with 1000 ml and 500 ml of ethyl acetate, respectively. The combined ethyl acetate extract was evaporated to dryness *in vacuo*. The residue was then dissolved in 2 ml of DMSO. A portion of the DMSO solution (1 ml) was subjected to semi-preparative HPLC with the following

conditions: column, YMC ODS-AQ 20x150 mm, S5; mobile phase, 0.1% formic acid in water (A) / methanol (B); gradient, 10% to 28% B in 5 min, 28% B for 30 min. The flow rate was 10 ml/min with UV detection at 240 nm. Fractions containing pure M20 were pooled and evaporated to a small volume with a rotary evaporator. After lyophilization, 23 mg of M20 (formic acid salt) was obtained as a white powder.

Characterization:

LC/MS: +ESI $[M+H]^+$: *m/z* 504; MS2: *m/z* 504→ *m/z* 417; MS3: *m/z* 504 → *m/z* 417 → *m/z* 381, 232, 260.

^{1}H NMR (700 MHz, *DMSO-d*$_6$) δ ppm 2.13 (s, 3H), 2.40 (s, 3H), 2.42 (t, *J* = 6.19 Hz, 2H), 2.48 (t, J=5.05 Hz, 4H), 3.50 (t, *broad*, 4H), 3.53 (t, *J*=6.19 Hz, 2H), 6.05 (s, 1H), 6.67 (d, *J* = 2.65 Hz, 1H), 6.76 (d, *J* = 2.65 Hz, 1H), 8.17 (s, 1H), 9.61 (s, 1H), 11.44 (s, 1H)

Preparation of dasatinib metabolite M24 by microbial biotransformation. From the frozen stock culture of *Streptomyces griseus* ATCC 10137, 2 ml was used to inoculate a 500 ml flask containing 100 ml of the malt extract medium. The flask was incubated for three days at 28°C on a rotary shaker operated at 250 rpm. One ml of the resulting culture was added to each of eleven 500 ml flasks containing 100 ml of the malt extract broth. The cultures were incubated at 28°C and 250 rpm for 47 hours. Dasatinib solution in DMSO (200 µl of a 48.9 mg/ml solution) was then added to each of the eleven flasks. The flasks were returned to the shaker and incubated for an additional 27 hours at 28°C and 250 rpm. The reaction cultures were pooled and extracted twice with 500 ml and 250 ml of ethyl acetate, respectively. The combined ethyl acetate extract was evaporated to

dryness *in vacuo*. The residue was then dissolved in 1.3 ml of DMSO. A portion of the DMSO solution (0.4 ml) were subjected to semi-preparative HPLC with the following conditions: column, YMC ProC18 20x250 mm, S5; mobile phase, 0.1% formic acid in water (A) / methanol (B); gradient, 15% to 27% B in 3 min, 27% B for 45 min. The flow rate was 10 ml/min with UV detection at 240 nm. Fractions containing pure M24 were pooled and evaporated *in vacuo* to a small volume with a rotary evaporator. After lyophilization, 2.8 mg of M24 (formic acid salt) was obtained as a white powder.

Characterization:

LC/MS: +ESI $[M+H]^+$: *m/z* 504; MS2: *m/z* 504→ *m/z* 486, 347; MS3: *m/z* 504 → *m/z* 486 → *m/z* 399, 347, 263.

^{1}H NMR (500 MHz, *DMSO-d_6*) δ ppm 2.40 (m, 5H), 2.48 (overlapped with DMSO peak), 3.51-3.54 (m, overlapped with water peak), 4.48 (s, 2H), 6.07 (s, 1H), 7.37 (t, *J* = 7.75 Hz, 1H), 7.46 (d, *J* = 7.75 Hz, 1H), 7.52 (d, *J* = 7.75 Hz, 1H), 8.23 (s, 1H).

RESULTS

Microbial screening plate. Based on their ability to catalyze oxidative transformations (references in Table 1, and unpublished data), twenty actinomycetes strains were used to construct the screening plate (Table 1). The strains were obtained from the American Type Culture Collection (Manassas, VA) (those strains with "ATCC" numbers) or from the Squibb Culture Collection (Bristol-Myers Squibb Company) (those strains with "SC" numbers). A large number of 24-well deep well screening plates were prepared and stored at -78^{o}C until needed. A single medium (malt extract medium) was employed for growing the cultures in the screening plate. Under these conditions, all the cultures

achieved good growth in two days. The final concentrations of the compounds utilized in these studies ranged from 0.1 to 0.3 mM and the incubations were typically run for 24 hours. This system provided a simple way to screen microbial strains with a small amount (~ 4 mg) of parent compound, the entire screening process was completed in four days including one day for analysis.

The ability of the microbial strains in the screening plate to selective catalyze the formation of metabolites was first tested in incubations with diclofenac. After a 24 hour incubation, diclofenac was depleted in most of the wells (Figure 3). Among the active strains, those in wells C2, C5, D1, and D2 selectively catalyzed 4'-hydroxylation to produce 4'-hydroxydiclofenac in high yield. In contrast, the strains in wells A3, A4, and D5 selectively catalyzed the formation of di-hydroxydiclofenac. Strains in other wells produced multiple metabolites in a non-selective manner.

Biosynthesis of BMS-587101 metabolite M6.

Screening was performed to identify strains which were capable of converting BMS-587101 to M6. Upon incubation with BMS-587101 in the screening plate, sixteen strains produced an HPLC/UV peak that had an identical UV spectrum (Figure 4) and HPLC retention time to M6 isolated from an RLM incubation (Figure 5). The strain in well C1 (*Actinomycetes sp*. SC15850) produced the largest amount of M6 and was therefore used to scale up the reaction in two shake flasks with a total of 200 ml malt extract medium. At a loading concentration of 0.18 mM, a reasonable production of M6 was obtained at 9 hr. Extending the reaction did not increase M6 concentration, rather, an additional peak

with an identical UV spectrum to that of M6 began to become more prominent (Figure 6). Therefore, the reaction was terminated at 12 hours. M6 (2.5 mg) was isolated from the reaction and analyzed by NMR and LC/MS to confirm that it was identical to M6 isolated from the RLM reaction (Table 2).

The peak at 9 min (3.5 mg) with an identical UV spectrum to M6 was also isolated from the microbial reaction. Accurate mass analysis suggested that it was an amide of M6. Incubation of the metabolite with pig liver esterase demonstrated that this product could be quantitatively converted to M6.

Due to variations among cultures and because M6 was converted to the amide by the cultures, it would be hard to stop the reaction at the ideal time to obtain the maximum yield of M6 from each flask. Therefore, the reaction was conducted to obtain a high yield of the amide, which was then hydrolyzed by pig liver esterase to yield M6. Using this two step process, more than 10 mg of M6 was generated, enabling the further evaluation of this metabolite.

Biosynthesis of dasatinib metabolites M20 and M24.

Dasatinib metabolites M20 and M24 both produced the same protonated molecule at *m/z* 504 and they often coeluted in LC/MS analyses. Their retention times were sensitive to sample and column conditions, and varied among analyses. Therefore, MS2 spectra of the *m/z* 504 ions were used to distinguish M20 and M24. M20 produced a product ion at *m/z* 417, while M24 yielded product ions at *m/z* 486 and *m/z* 347. Thus, both MS and UV

absorbance at 320 nm were used to determine that strains in wells A3, A4, C5, D1, D2, D3, and D4 were able to catalyze conversion of dasatinib to M20 and M24 in useful amounts (Figure 7). HPLC/UV analysis with dasatinib HPLC method 2 indicated that the strain in well A4 yielded the highest amounts of M20 and a high ratio (~4:1) of M20 to M24. The strain in this well, *Streptomycetes. sp.* SC15761, was therefore chosen for scaling up to a larger reaction. More than twenty milligrams of M20 was prepared from approximately 0.5 liter microbial incubation with *Streptomycetes. sp.* SC15761. NMR and LC/MS/MS analyses confirmed that it was identical to M20 isolated from an HLM reaction (Table 3). Furthermore, M20 isolated from both the microbial biotransformation and M20 isolated from an HLM incubation coeluted under various HPLC conditions.

The amounts of M24 produced by the strains in wells A4 and D4 were similar; however, the amount of M20 produced by the strain in well D4 was much lower than the strain in well A4. Because M20 and M24 had very similar chromatographic properties, high level of M20 would make purification of M24 very difficult. Therefore, the strain in well D4, *Streptomyces griseus* ATCC 10137, was chosen for production of M24. M24 (2.8 mg) was prepared from an approximately 0.3 liter microbial incubation of *Streptomyces griseus* ATCC 10137. The identity of the microbial synthesized M24 was confirmed by NMR and LC/MS/MS analyses (Table 4), and coelution with M24 isolated from an HLM incubation under various HPLC conditions.

DISCUSSION

Many fungal and bacteria strains with the capacity for oxidative biotransformation are useful for the biosynthesis of otherwise difficult to prepare chemicals. Much of the knowledge about these microbial techniques comes from screening efforts to identify strains that metabolize steroid-like molecules. In fact, the microbial hydroxylation of steroids has been a synthetic route for the production of several steroids since the early 1950s (Peterson, 1952). Evidence indicates that many fungi possess numerous genes that encode enzymes capable of oxidative biotransformations, and that many of these enzymes are monooxygenases belonging to the cytochrome P450 superfamily (van den Brink, 1998). While cultures of these fungi may provide a convenient and abundant capacity for enzymatic oxidations, fermentations in a microtiter plate or a shake flask can be difficult because the cultures tend to form large mycelium aggregates. Cross-contamination when using plate formats is also an issue because spores formed on the surface of mycelium aggregates or in the liquid can be transported from well to well. On the other hand, actinomycetes strains do not have such limitations, as they are often easy to grow and do not form large mycelium aggregates. P450 enzymes, as well as other monooxygenases and dioxygenases, have been identified in actinomycetes and shown to be capable of oxidative transformation of xenobiotics (Sariaslani, 1992; Trower, 1992; Lamb, 2002; Basch, 2006). These attributes illustrate that actinomycetes strains offer a balance of ease of use and substantial biotransformation capability.

Much of the work in microbial models of mammalian metabolism has focused on finding one or a limited number of “super” strains capable of producing most of the mammalian metabolites of a given drug or drug candidate, so that the majority of the metabolites of

interest can be obtained with a minimal number of incubations (Cannell, 1995; Joanna, 1999; Zhang, 2006; Zmijewski, 2006). Alternatively, for the purpose of preparing specific key mammalian metabolites it may be advantageous to have an array of microbial strains with differing selectivities for the separate production of individual metabolites. If the interest is in preparing one or a very limited number of metabolites, a strain capable of producing many metabolites lowers the yield and increases the difficulty of purification. The advantages of selective metabolite formation was demonstrated with diclofenac, the metabolism of which has been well characterized in various biological systems including microbial systems. When diclofenac metabolism was screened in the microbial panel, the strains in wells A1-A5, B1-B3, C1, C3, C4, D4, and D5 were shown to be highly efficient in the turnover of diclofenac (Figure 3), but these strains were not as useful as those in wells C2, C5, D1, and D2 for preparing 4'-hydroxydiclofenac. This illustrates the value of identifying those strains with a high degree of selectively toward the formation of a specific metabolite. Each actinomycetes strain bears oxygenases with different regio- and stereo-selectivity, and accordingly, different substrate specificities. It is possible to take advantage of the variety in a limited number of highly active strains to produce a wide range of oxidative metabolites of interest without sacrificing yield and purity. The key to the successful use of this approach is the ability to rapidly screen microbial strains. The screening plate system introduced here provides an efficient way to access the power of a microbial strain array.

When selecting strains for a screening plate, it is critical to consider both the oxidative capabilities and the growth characteristics of the strain. There is a wealth of literature

reports on highly active fungi and bacteria strains, and these various strains can be roughly divided into two groups: the first group is those known to produce natural products with oxidative steps in the biosynthetic pathways; and the second group is those known to perform oxidative transformations of xenobiotics. Many of these strains can be obtained from culture collections such as the American Type Culture Collection (Manassas, VA) (strain identifier starting with "ATCC") and the National Center for Agricultural Utilization Research (Peoria, IL) (strain identifier starting with "NRRL"). If the strain reported is not available from the culture collections, other strains in the same genus may be obtained from the culture collections and will likely have similar biotransformation properties. The growth characteristics of the strains should be chosen such that strains in the same plate have similar growth rates. To further simplify the screening procedures, the strains should be able to grow in the same medium. The malt extract medium described in this report is able to support the growth of various actinomycetes strains and supports good oxidative biotransformation activity. The oxidative capacity of several of the strains used in this study have been previously demonstrated (Table 1, strains with references). The other strains have not been previously described but were found to possess useful oxidative activities (data not shown). The strains described here are one possible starting point for screening plates. There are likely to be other strains of actinomycetes capable of producing similar results.

The actinomycetes strains used in this study grew well in the 24-well deepwell plate. Plate formats with larger number of wells would allow screening of more strains with each plate, but low aeration rates would negatively affect growth of cultures and

efficiency of biotranformation unless modifications were made to the fermentation conditions (Duetz, 2001). Additionally, the experimental design described in this study utilizing 20 high activity strains has been shown to be sufficient to find conditions under which most metabolites of interest can be produced. This study and a recent study showed that collectively the microbial enzymes encompassed by the 20 strains in Table 1 were able to mimic mammalian P450 enzymes and perform typical P450 probe reactions, such as the 4'-hydroxylation of diclofenac and the 1'- or 4-hydroxylation of midazolam (Li, 2005).

After analysis of the screening reactions, the selection of strains for scale-up reactions was based on the yield of desired metabolites as well as the number and relative proportions of undesired metabolites. Scaling up from microtiter plates to shake flasks (100 ml culture in 500-ml flask) was relatively straightforward, probably because the oxidative biotranformations proceeded faster in the flask due to higher aeration rates. Biotranformations in flasks can be used to make gram quantities of a desired product, as shown for the 21-hydroxylation of epothilone B (Li, 2004).

BMS-587101 is a small molecule antagonist of the leukocyte function-associated antigen-1 (Potin, 2006). During the development of BMS-587101 it was determined that M6 was a circulating metabolite in rat, dog and human (data not shown). MS analysis indicated that it was two mass units less than BMS-587101. The possible sites for this net dehydrogenation were limited in the molecule and therefore the likely site was determined to be between C-16 and C-17. This was confirmed by NMR analysis of

material purified from an RLM incubation. Milligram quantities of this metabolite were needed for further characterization but the yield of M6 in RLM (0.2%) was extremely low and it was not feasible to use any other LM incubation for a larger scale preparation. Chemical synthesis of M6 would have required considerable effort because it would require a completely revamped synthetic route to install a double bond between C-16 and C-17 (Potin, 2006). The microbial biosynthesized material allowed for the necessary initial characterization of the metabolite.

It is interesting to note the conversion of the carboxylic acid moiety of M6 and BMS-587101 to amides by the microbial cultures. While amide formation from a carboxylic acid of an amino acid has been reported (Steffensky, 2000), there are only a few reports of this type of transformation in bacteria. In the case of amidation of polyaromatic carboxylic acids in *Bacillus cereus*, it was shown that the nitrogen atom of the amides came from an amino groups of an amino acid and not from ammonia or an alkylamine (Maruyama, 2001).

Dasatinib is a potent inhibitor of SRC and BCR-ABL kinases (Das, 2006). It has been approved in US and Europe for the treatment of chronic myelogenous leukemia (CML) in Gleevec® (imatinib)-resistant and imatinib-sensitive patients. Hydroxylation on the 2-chloro-6-methylphenyl ring to form metabolites M20 and M24 was one of the major routes identified in the *in vitro* and *in vivo* biotransformation of dasatinib (Christopher, 2007; Cui, 2007). M20 accounted for approximately 31% of the administered dose in humans (Christopher, 2007). Quantities of M20 and M24 generated in HLM incubations

were sufficient for structural elucidation by NMR analysis (Cui, 2007). However, a larger quantity of M20 and M24 was needed for activity testing and to serve as an analytical standard in the analysis of animal and human samples. While efforts towards chemical synthesis of these metabolites met with great difficulty, the microbial technique provided a relatively facile means for rapid generation of M20 and M24.

It is not clear whether a single microbial enzyme in each strain was responsible for formation of both M20 and M24, or if the two metabolites were products of multiple enzymes. Each microbial strain that produced M20 also generated M24, which may imply that they are formed by a single enzyme. Obviously, variations existed among the strains, as each strain produced a different ratio of M20 to M24.

In summary, the 24-well plate system described in this study is an extremely useful and efficient method for rapidly screening actinomycetes strains for biotransformation activity. The utility of this method was demonstrated with two examples in which mammalian oxidative metabolites of two development-stage compounds were produced by microbial routes. In both of these examples the metabolites were not readily accessible by chemical synthesis, and scale up of mammalian systems would have required significant resources. A simple shake-flask microbial biotransformation method subsequent to the initial screening was shown to be readily capable of producing up to 20 mg of metabolite with a half liter fermentation, and was used for obtaining material for initial metabolite characterization work such as testing for pharmacological activity or as a standard for the development of quantitative LC/MS assays.

ACKNOWLEDGEMENTS

The authors thank Drs. Lisa Christopher and Suresh Yeola for providing metabolite information on BMS-587101 and dasatinib. We appreciate the efforts of Dr. Xiaohua Huang, Dr. Feng Qiu and Ms. Cindy Li in the completion of NMR analyses described.

REFERENCE

Abourashed EA, Clark AM and Hufford CD (1999) Microbial Models of Mammalian Metabolism of Xenobiotics: An Updated Review. *Curr. Med. Chem.* 6:359-374.

Azerd R (1999) Microbial Models for the Drug Metabolism. *Adv. Biochem. Eng. Biotechnol*. 63:169-218.

Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG and Shipley LA (2002) Drug Metabolites in Safety Testing. *Toxicol. Appl. Pharmacol.* 182:188–196.

Basch J, Chiang S-J (2006) Cloning and expression of a cytochrome P450 hydroxylase gene from *Amycolatopsis orientalis*: hydroxylation of epothilone B for the production of epothilone F. *J. Ind. Microbiol. Biotechnol*. 34:171-176.

Chen TS, Arison BH, Wicker LS, Inamine ES, Monaghan RL (1992) Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. *J. Antibiot*. 45:118-123.

Christopher L, Cui D, Wu C, Luo R, Manning J, Bonacorsi SJ, Lago M, Allentoff A, Lee FYF, McCann B, Reitberg D, Galbraith S, He K, Barros A, Blackwood-Chirchir A,

Humphreys WG and Iyer RA (2008) Metabolism and Disposition of Dasatinib after Oral Administration to Humans. *Drug Metab. Dispos*. submitted.

Cui D, Li W, Chistopher L, Barros A, Arora V, Zhang H, Wang L, Zhang D, Manning JA, He K, Fletcher AM, Ogan M, Lago M, Bonacorsi SJ, Humpheys WG, and Iyer RA (2008) Biotransformation of [^{14}C]Dasatinib: In Vitro Studies in Rat, Monkey and Human and Disposition after Adminstration to Rats and Monkey. *Drug Metab. Dispos*. submitted.

Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish J (2006) C2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of *N*-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent *pan*-Src Kinase Inhibitor. *J. Med. Chem***.** 49:6819-6832.

Davis-Bruno KL and Atrakchi A (2006) A Regulatory Perspective on Issues and Approaches in Characterizing Human Metabolites. *Chem. Res. Toxicol*. 19:1561 - 1563.

Duetz WA and Witholt BW (2001) Effectiveness of orbital shaking for the aeration of suspended bacterial cultures in square-deepwell microtiter plates. *Biochem. Eng. J*. 7:113-115.

Ferrer JC, Calzada V and Bonet JJ (1990) Microbiologic oxidation of estratrienes and estratetraenes by *Streptomyces roseochromogenes* ATCC 13400. *Steroids* 55:390-394.

Guengerich FP (2006) Safety Assessment of Stable Drug Metabolites. *Chem. Res. Toxicol*. 19:1559 - 1560.

Humphreys WG and Unger SE (2006) Safety Assessment of Drug Metabolites: Characterization of Chemically Stable Metabolites. *Chem. Res. Toxicol*. 19:1564 - 1569.

Lamb DC, Skaug T, Song H-L, Jackson CJ, Podust LM, Waterman MR, Kell DB, Kelly DE, Kelly SL (2002) The Cytochrome P450 Complement (CYPome) of *Streptomyces coelicolor* A3(2). *J. Biol. Chem*. 277:24000-24005.

Li W, Matson JA, Xiaohua H, Lam K-S, McClure GA. (2004) Microbial transformation method for the preparation of an epothilone. US patent, US 6,780,620 B1.

Li W, Josephs JL, Humphreys WG (2005) Metabolite Generation and Characterization *via* Microbial Biotransformation with Actinomycetes. *Drug Metab. Rew*. 37(sup 2):196. Abstract #351, 13th North American ISSX meeting, Maui, Hawaii, USA.

Maruyama R, Kawata A, Ono S, Nishizawa M, Ito S, Inoue M (2001) Effects of amino acids on the amidation of polyaromatic carboxylic acids by Bacillus cereus. *Biosci. Biotechnol. Biochem.* 65:1761-1765.

Moody JD, Freeman JP and Cerniglia CE (1999) Biotransformation of Doxepin by *Cunninghamella elegans. Drug Metab. Dispos*. 27:1157-1164.

Moody JD, Freeman JP, Fu PP and Cerniglia CE (2002) Biotransformation of Mirtazapine by *Cunninghamella elegans. Drug Metab. Dispos*. 30:1274-1279.

Okazaki T, Serizawa N, Enokita R, Torikata A, Terahara A (1983) Taxonomy of actinomycetes capable of hydroxylation of ML-236B (compactin). *J. Antibiot*. 36:1176-1183.

Peterson DH, Murray HC, Eppstein SH, Reineke LM, Weintraub A, Meister PD, Leigh HM (1952) Microbiological transformations of steroids. I. Introduction of oxygen at carbon-11 of progesterone. *J. Am. Chem. Soc*. 74:5933-5936.

Potin D, Launa M, Monatlik F, Malabre P, Fabreguettes M, Fouquet A, Maillet M, Nicolai E, Dorgeret L, Chevallier F, Besse D, Dufort M, Caussade F, Ahmad SZ, Stetsko DK, Skala S, Davis PM, Balimane P, Patel K, Yang Z, Marathe P, Postelneck J, Townsend RM, Goldfarb V, Sheriff S, Einspahr H, Kish K, Malley MF, DiMarco JD, Gougoutas JZ, Kadiyala P, Cheney DL, Tejwani RW, Murphy DK, Mcintyre KW, Yang X, Chao S, Leith L, Xiao Z, Mathur A, Chen B-C, Wu D-R, Traeger SC, McKinnon M, Barrish JC, Robl JA, Iwanowicz EJ, Suchard SJ, Dhar TGM (2006) Discovery and Development of 5-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101)-

A Small Molecule Antagonist Leukocyte Function Associated Antigen-1. *J. Med. Chem.* 49:6946-6949.

Sariaslani FS, Omer A (1992) Actinomycete cytochromes P-450 involved in oxidative metabolism: biochemistry and molecular biology. *Crit. Rev. Plant Sci*. 11:1-16.

Smith DA and Obach RS (2006) Metabolites and Safety: What Are the Concerns, and How Should We Address Them? *Chem. Res. Toxicol*. 19:1570-1579.

Smith RV and Rosazza JP (1974) Microbial models of mammalian metabolism. Aromatic hydroxylation. *Arch. Biochem. Biophys*. 161:551-558.

Smith RV, Davis PJ, Kerr KM (1983) Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone. *J. Pharm. Sci*. 72:733-736.

Steffensky M, Li S-M, Heide L (2000) Cloning, overexpression, and purification of novobiocic acid synthetase from Streptomyces spheroides NCIMB 11891. *J. Biol. Chem.* 275:21754-21760.

Stierlin H, Faigle JW, Sallmann A, Ku¨ng W, Richter WJ, Kriemler .P, Alt KO, Winkler T (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Identification and isolation of principal metabolites. *Xenobiotica* 9:601–610.

Tombo GMR, Ghisalba O, SChar H-P, Frei B, Maienfisch P, O'Sullivan AC (1989) Diastereoselective microbial hydroxylation of milbemycin derivatives. *Agric. Biol. Chem.* 53:1631-1635.

Trower MK, Lenstra R, Omer C, Buchholz SE, Sariaslani FS (1992**)** Cloning, nucleotide sequence determination and expression of the genes encoding cytochrome P-450soy (soyC) and ferredoxinsoy (soyB) from Streptomyces griseus. *Mol. Microbiol.* 6:2125-2134.

U.S. Food and Drug Administration (2005) Draft Guidance to Industry Safety Testing of Drug Metabolites. www.fda.gov/cder/guidance.

van den Brink HJM, van Gorcom RFM, van den Hondel CAMJJ, Punt PJ (1998) Cytochrome P450 Enzyme Systems in Fungi. *Fungal Genet. Biol.* 23:1-17.

Xie ZY, Huang HH and Zhong DF (2005) Biotransformation of pantoprazole by the fungus *Cunninghamella blakesleeana*. *Xenobiotica.* 35:467-477.

Zhang D, Zhang H, Aranibar N, Hanson R, Huang Y, Cheng PT, Wu S, Bonacorsi S, Zhu M, Swaminathan A and Humphreys WG (2006) Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. *Drug Metab. Dispos.* 34**:**267–280.

Zmijewski M, Gillespie TA, Jackson DA, Schmidt DF, Yi P, and Kulanthaivel P (2006) Application of Biocatalysis to Drug Metabolism: Preparation of Mammalian Metabolites of a Biaryl-bis-sulfonamide AMPA (α-Amino-3Hydroxy-5-Methylisoxazole-4-propionic Acid) Receptor Potentiator Using *Actinoplanes missouriensis*. *Drug Metab. Dispos.* 34**:**925–931.

FOOTNOTE

[1] Present address: Department of Pharmacokinetics & Drug Metabolism, Amgen, Inc. Thousand Oaks, CA 91320

[§]Portions of this work were presented at the 13th North American ISSX Meeting, Oct 23-27, 2005, Maui, Hawaii (Abstracts 351).

Legends of Figures

Figure 1. Structures of BMS-587101, metabolite M6 and amide of M6.

Figure 2. Structures of dasatinib and metabolites M20, M24.

Figure 3. HPLC/MS chromatograms of microbial reaction extracts with diclofenac in the screening plate. Microbial strains are identified with well positions. Di-hydroxy-diclofenac, hydroxydiclofenac (unidentified isomer), 4'-hydroxydiclofenac, and diclofenac are marked with boxes 1, 2, 3, and 4, respectively.

Figure 4. UV absorbance spectra of BMS-587101 and metabolite M6.

Figure 5. HPLC/UV chromatograms of microbial reaction extracts with BMS-587101 in the screening plate. Microbial strains are identified with well positions. BMS-587101, the amide derivative of M6, and M6 eluted at 7.7 min (box 1), 8.9 min (box 2), and 10.2 min (box 3), respectively.

Figure 6. HPLC/UV chromatograms of extracts from the reaction of BMS-587101 in *Actinomycetes sp*. SC15850 (well C1) at different reaction times.

Figure 7. HPLC/MS chromatograms of microbial reaction extracts with dasatinib in the screening plate (obtained with dasatinib HPLC method 1). Microbial strains are identified with well positions. Dasatinib eluted at 25 min (boxed). M20 and M24 coeluted and their retention time varied among the chromatographs (marked with an arrow).

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Table 1. Microbial strains contained in the screening plate

Position in the screening plate	SC number	ATCC number	Strain	Reference
A1		53771	*Actinoplanes sp.*	Chen, 1992
A2		35204	*Nocardia autotrophica*	Okazaki, 1983
A3		35203	*Nocardia autotrophica*	Okazaki, 1983
A4	15761		*Streptomycetes sp.*	
A5		13400	*Streptomycetes roseochromogenus*	Ferrer, 1990
B1		31560	*Streptomyceste violascens*	Tomobo, 1989
B2		25453	*Streptomycetes flocculus*	Smith, 1983
B3	15847	PTA-1043	*Amycolatopsis orientalis*	Li, 2004
B4	15848		*Actinomycetes sp.*	
B5	15849		*Actinomycetes sp.*	
C1	15850		*Actinomycetes sp.*	
C2	15851		*Actinomycetes sp.*	
C3	15852		*Actinomycetes sp.*	
C4	15853		*Actinomycetes sp.*	
C5	15837		*Actinomycetes sp.*	
D1	15838		*Actinomycetes sp.*	
D2	15839		*Actinomycetes sp.*	
D3	15840		*Actinomycetes sp.*	
D4		10137	*Streptomyces griseus*	Smith, 1983
D5		13273	*Streptomyces griseus*	Trower, 1992

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Table 2. ^{1}H and ^{13}C NMR chemical shift assignment of BMS-587101 metabolite M6 produced by RLM:



Position	**^{1}H ppm (*d4*-methanol: δ 3.30 ppm)**	**^{13}C ppm (*d4*-methanol: δ 49 ppm)**	**Key HMBC (^{1}H - ^{13}C) correlations**
2	8.13 (s, 1H)		
3		134	
4	7.45 (s, 1H)	129	142 (C-5)
5		142	
8	a, 4.53 (d, J = 15.4 Hz, 1H), b, 4.68 (d, J = 15.4 Hz, 1H)	49	60 (C-10), 142 (C-5), 148 (C-16)
9 (N)			
10	a. 3.76 (d, J = 12.4 Hz, 1H), b. 3.81 (d, J = 12.4 Hz, 1H)	60	76 (C-11), 106 (C-17), 148 (C-16), 174 (C-15)
11		76	
13		154	
15		174	
16	7.62 (s, 1H)	148	60 (C-10), 76 (C-11), 106 (C-28)
17		106	
19	2.81 (s, 3H)		154 (C-13)
22 and 26	7.53 (d, J = 1.8 Hz, 2H)		
23 and 25			
24	7.50 (t, J = 1.8, 1H)		
29 and 33	7.55 (d, J = 8.6 Hz, 2H)	123	120 (C-30 and C-32)
30 and 32	7.17 (d, J = 8.8 Hz, 2H)	120	106 (C-17), 123 (C-29 and C-33)

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Table 3. ^{1}H, ^{13}C and ^{15}N NMR chemical shift assignment of dasatinib metabolite M20 produced by microbial biotransformation



Position	**^{1}H ppm (*d6*-DMSO, δ 2.50 ppm)**	**^{13}C ppm (*d6*-DMSO, δ 39.5 ppm)**	**^{15}N ppm (*d6*-DMSO, referenced to $^{15}NH_4{}^{15}NO_3$ at δ20.7 and δ376.3 ppm)**
2		162.2	
3 (N)			267.8
4	8.17 (s, 1H)	140.9	
5		126.3	
6 (N)	11.44(b, s, 1H)		119.1
7		157.1	
8 (N)			226.7/237.5
9		165.6	
10 (N)			226.7/237.5
11		163.1	
12	6.05 (s, 1H)	82.9	
13		160.7	
15	2.40 (s, 1H)	26.0	
16 (N)			87.5
17 and 21	3.50 (b, t, 4H)	44.0	
18 and 20	2.48 (t, J = 5.05 Hz, 4H)	53.2	
19 (N)			43.7
22 (N)	9.61 (s, 1H)		115.5
23		125.2	
24		132.8	
25	6.76 (d, J = 2.65 Hz, 1H)	113.8	
26		156.9	
27	6.67 (d, J = 2.65 Hz, 1H)	116.3	
28		139.6	
29	2.42 (t, J = 6.19 Hz, 2H)	60.7	
30	3.53 (t, J = 6.19 Hz, 2H)	59.0	
34	2.13 (s, 1H)	18.9	

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Table 4. ^{1}H, ^{13}C and ^{15}N NMR chemical shift assignment of dasatinib metabolite M24 produced by microbial biotransformation



Position	^{1}H ppm (*d6*-DMSO, δ 2.50 ppm)	^{13}C ppm (*d6*-DMSO, δ 39.5 ppm)
2		160.5
3 (N)		
4	8.23 (s, 1H)	141.4
9		165.5
12	6.07 (s, 1H)	83.1
13		163.1
15	2.40[a]	26.2
17 and 21	3.50[a]	44.1
18 and 20	2.48[a]	53.1
23		131.4
24		132.6
25	7.46 (d, J = 7.75 Hz, 1H)	127.8
26	7.37 (t, J = 7.75 Hz, 1H)	128.3
27	7.53 (d, J = 7.75 Hz, 1H)	125.7
28		143.7
29	2.41[a]	60.7
30	3.53[a]	59.0
33	4.48 (s, 1H)	59.8

[a:] no integration or coupling constant data are available due to peak overlap

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 1



BMS-587101



M6



Amide of M6

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 2



Dasatinib



M20



M24

DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 3



DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 4



DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 5



DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 6



DMD Fast Forward. Published on January 28, 2008 as DOI: 10.1124/dmd.107.019570
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 7